- John Podesta eats crow: ‘I apologize to Speaker Boehner’
- U.S., China race to finish line on ‘invisibility cloak’
- Obama ‘cavalier’ in hiding foreign aid order, judge rules
- Prince Charles: Muslims are driving Christians from Mideast through persecution
- Gitmo’s first commander: Close the prison down
- Google’s newest photography find: Just wink and shoot
- Detroit’s Heidelberg art project hit by 8 fires in 8 months
- Pa. police pull people over for random DNA tests for feds
- NASA pushing hard to get back into space game
- Harvard student to face federal charges for bomb hoax
Latest Health_Medical_Pharma Items
When her stroke hit, Edna Wooten somehow stopped her car. Then her grown daughter ignored her slurred protests and raced her to the hospital _ in time for a drug to dissolve the blood clot causing her stroke.
Parents who say their daughter allegedly suffered serious health problems from a childhood vaccine are trying to persuade the Supreme Court to allow them to sue the manufacturer.
Pfizer says it will buy a company specializing in pain drugs in a $3.6 billion deal meant to shore up the portfolio of the world's largest drug company.
Pfizer Inc. said Tuesday it will buy a company specializing in pain drugs in a $3.6 billion deal meant to shore up the portfolio of the world's largest drug company.
A look at Pfizer Inc.'s plan to buy King Pharmaceuticals Inc.
Pfizer's purchase of King Pharmaceuticals announced Tuesday represents a $3.6 billion investment in an emerging class of painkillers that are designed to be less addictive than older pills such as OxyContin. The new products have been touted by federal health officials as an important way to curb prescription drug abuse, but they are relatively untested in the marketplace.
If you knew you had one year to live, would you have medical tests you didn't need?
In a story Oct. 11, The Associated Press reported that the Food and Drug Administration denied approval to JZP-6, a Jazz Pharmaceuticals drug candidate intended to treat fibromyalgia. The drug is approved under the name Xyrem as a treatment for narcolepsy and cataplexy.
Drugmaker Alkermes Inc. said Tuesday it has received U.S. approval to market its addiction medication for use in patients addicted to narcotics like heroin and morphine.